|
|
|
|
|
|
|
|
|
|
|
29.10.25 - 21:21
|
Bio-Rad Reports Third-Quarter 2025 Financial Results (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025.
“During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated Norman Schwartz, Bio-Rad's Chairman and CEO. "Despite ongoing challenges in academic research and biotech funding, and the resulting reduced demand for instruments, our teams delivered solid results in Q3. Our ongoing focus on disciplined cost management contributed to a better-than-expected operating margin."
Financial Results Highlights
GAAP Results
Q3 2025
Q3 2024
Revenue (millions)
$
653.0
$
649.7
Gross margin
52.6
%
54.8
%
Income from operations
$
65.3
$
64.5
Net income (loss) (millions)
$
(341.9
)
$
653.2
Income (loss) per diluted shar...
|
|
|
|
|
|
|
16.10.25 - 23:36
|
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.
To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics m...
|
|
|
|
|
|
|
|
|
|
|
31.07.25 - 22:24
|
Bio-Rad Reports Second-Quarter 2025 Financial Results (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025.
Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital™ PCR offering with the recent launch of our QX Continuum™ system complemented by the QX700™ series of acquired instruments.”
Financial Results Highlights
GAAP Results
Q2 2025
Q2 2024
Revenue (millions)
$
651.6
$
638.5
Gross margin
53.0
%
55.6
%
Income from operations
$
77.1
$
101.5
Net income (loss) (millions)
$
317.8
$
(2,165.5
)
Income (loss) per diluted share
$...
|
|
|
|
|
28.07.25 - 22:21
|
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company.
Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing resp...
|
|
|
17.07.25 - 22:21
|
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025 (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2025 on Thursday, July 31, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.
To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics mark...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
